Learning Objectives
At the conclusion of this activity, participants will be able to:

• Prescribe medications without being subject to undue influence by drug company marketing
• Select the most evidence-supported medications for efficacy and safety for patients with benzodiazepine use and use disorders.
• Select the most evidence-supported medications for efficacy and safety for anxiety in the elderly.

• Select the most evidence-supported medications for efficacy and safety for patients with eating disorders.
• Understand the acute and long term psychiatric sequelae of SARS CoV-2 Infection and the role of psychopharmacology that may be useful
• Select the most evidence-supported medications for efficacy and safety for patients with Alzheimer’s Disease

Massachusetts Psychiatric Society’s
33rd Annual Psychopharmacology Update

Program Overview
Each year the psychopharmacology update course chair and cochair review feedback from the previous year including suggestions for topics of interest. Also, the chair has extensive experience consulting with psychiatrists who have psychopharmacology questions and becomes aware of prescribing issues that are not well understood by practitioners. From these sources a set of presentations was developed. The program begins with a review of 10 Evidence-Based Practices that differ from what many clinicians do. A second speaker will focus on benzodiazepine use and use disorders. After a break, a speaker will update attendees on the psychopharmacology of anxiety in the elderly. A keynote speaker, Michael Ostacher, MD from Stanford University School of Medicine in Palo Alto, CA, will review updates to the VA practice guideline for bipolar disorder. After a lunch break, the program continues with the Keynote Speaker, Erica Berlin Baller, who is from the University of Pennsylvania. Dr. Baller will discuss the acute and long term psychiatric sequelae of SARS CoV-2 Infection and the role of psychopharmacology. The final lecture will be on the topic of the psychopharmacology of Alzheimer’s disease treatment. The program will end with questions and answers on any topic in psychopharmacology with a panel of the day’s speakers.

AMA Credit Designation Statement
The Massachusetts Psychiatric Society designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement
The Massachusetts Psychiatric Society is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
Program Schedule

8:15-8:30 a.m.   Welcome and Introduction
David N. Osser, MD, Activity Chair
Anderson Chen, MD, Activity Co-Chair

8:30-9.30 a.m.   10 Evidence-Based Practices that Differ from what Many Clinicians Do
David N. Osser, MD

9:30-10:30 a.m.   Benzodiazepine Use and Use Disorders
Michael A. Dawes, MD

10:30-10.45 a.m.   BREAK

10:45-11:45 a.m.   Psychopharmacology of Anxiety in the Elderly
Anderson Chen, MD

11:45-12:45 p.m.   Psychopharmacology of Bipolar Disorder: Update on the Practice Guidelines of the VA
Michael J. Ostacher, MD, MPH, MMSc, DFAPA

12:45-1:30 p.m.   LUNCH

1:30-2.30 p.m.   Acute and Long-Term Psychiatric Sequelae of SARS CoV-2 Infection
Erica Berlin Baller, MD, MS,

2:30-2:40 p.m.   BREAK

2:40-3:40p.m.   Psychopharmacology of Alzheimer’s Disease
Brent P. Forester, MD, MSc

3:40-4:10p.m.   More Questions and Answers
Panel of the Speakers
33rd Annual Psychopharmacology Update

REGISTRATION FEE

[ ] MPS/APA/MMS MEMBER          $90
[ ] RESIDENT/FELLOW/STUDENT     $20
[ ] NON-MEMBER          $110

CLICK HERE TO REGISTER. Please note the link for the conference will be sent on November 4. If you are unable to register online, please contact the office to register by phone.

Questions?
Call (781) 237-8100, 8 a.m.–4 p.m. Monday thru Friday